ImmunityBio Stock Plunges 22% After Its Adjusted Quarterly Loss Widens

ANKTIVA product revenue grew 53%, while research spending rose and the company reported success in a bladder-cancer trial.

Share
ImmunityBio Stock Plunges 22% After Its Adjusted Quarterly Loss Widens

ImmunityBio, which develops and sells immune-system treatments for cancer and infectious diseases, plunged 22.06% to $6.73 in Monday trading, as of 9:42 AM ET, losing $2 billion in market value. The drop followed a wider adjusted loss in the company's Monday earnings filing, even with higher ANKTIVA sales.

Sales Grow, Research Costs Rise

ImmunityBio lost $97.9 million in the third quarter excluding valuation changes and stock compensation, compared with a $72.4 million loss a year earlier. Research spending reached $71.5 million, up from $51.2 million.

ANKTIVA generated $48.7 million in net product revenue for the quarter, a 53% increase. The company's main product is a protein drug for bladder cancer that no longer responds to BCG, a standard treatment.

Net ANKTIVA sales brought in about $113 million for full-year 2025. ImmunityBio also has vaccines and natural killer cell treatments in development.

A Big Rally Under Pressure

IBRX shares were on pace for their second decline of 10% or more this month in Monday trading, as of 9:42 AM ET. The company's market value stood at $7.13 billion in Monday trading, as of 9:42 AM ET.

The selloff cut into a large earlier advance: at Friday's close, ImmunityBio shares were up 336% year to date, against an 8% gain for the S&P 500. But the stock had fallen 11% over the previous month through Friday's close and entered Monday's session 25% below its highest close of the past year.

Bladder-Cancer Trial Meets Its Goal

In a separate Monday update, ImmunityBio said ANKTIVA combined with BCG met the main goal of a randomized bladder-cancer trial. The company targets an FDA approval application by year-end to make the treatment available to bladder-cancer patients earlier in treatment.

ANKTIVA has approvals in the US, UK and Saudi Arabia, conditional authorization in the EU, and authorization for use in 33 countries. Saudi Arabia has also conditionally approved it for metastatic lung cancer. Insurance coverage encompassed more than 240 million lives as of December 2025.

The company's next stated step is its targeted year-end approval application for earlier bladder-cancer treatment.

Sources

More on ImmunityBio

All ImmunityBio (IBRX) coverage →